Tandem Diabetes Care Inc at UBS Genomics 2.0 and MedTech Innovations Summit Transcript
Good morning, everyone. Thank you for joining us for the last session of the morning. I am Danielle Antalffy. I'm the medtech analyst in the U.S. here at UBS and very excited to have with us the company I've known for a very long time, Tandem Diabetes. CEO, John Sheridan; CFO, Leigh Vosseller. Thank you guys for joining us. I know you drove very far to get here.
Thanks for having us.
Questions & Answers
You are welcome. So one of the questions I want to ask you guys after several years of a very strong stock performance. It's been a tough few quarters here. And I just wanted to maybe start with a question I actually usually end with. And that is, what do you think investor sell-side might be missing about the Tandem story that has been driving some of the stock underperformance recently.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |